Nordic Biotech Innovation Meets Global Impact: Diamyd Medical on the SACC NE Podcast
By Ombeline Ragoucy, Investment Associate
March 18, 2026
A recent episode of the SACC New England Podcast highlights how Nordic life science innovation continues to shape global healthcare, with a particular focus on advances in diabetes research and the growing connection between European biotech companies and the U.S. market.
The episode features Dr. Karin Rosén, physician-scientist and board member of Swedish biotechnology company Diamyd Medical, in conversation with moderator Julie Ames, a strategic communications advisor with extensive experience across life sciences and public policy. Together, they explore how emerging insights into the immune system are opening new possibilities for treating autoimmune diseases such as type 1 diabetes.
Dr. Karin Rosén, Physician-Scientist and Board Member of Diamyd Medical.
Julie Ames, Strategic Communications Executive and Podcast Moderator.
Diamyd Medical is developing an investigational therapy designed to help preserve the body’s own insulin production by retraining the immune system — an approach based on research into immune tolerance that has been recognized at the highest levels of scientific discovery. The company is currently advancing this therapy through a Phase 3 clinical trial in both the United States and Europe, focusing on patients with a specific genetic profile and using C-peptide as a key marker of insulin production. This progress is further underscored by recent written feedback from the U.S. FDA, which allows Diamyd Medical to analyze its primary results nine months earlier than originally planned.
The discussion also highlights the broader strengths of the Nordic life science ecosystem, where strong academic research, close collaboration between healthcare systems and industry, and an international outlook help translate scientific discovery into clinical progress. Companies such as Diamyd Medical exemplify how this ecosystem enables innovation to scale globally while addressing significant unmet medical needs.
As the conversation makes clear, advancing complex therapies requires not only strong science but also global collaboration, regulatory engagement, and deep understanding of international healthcare systems. Through initiatives like the SACC New England Podcast, these transatlantic connections continue to strengthen the path from discovery to patient impact.
Listen to the full podcast episode on Spotify here or directly scan this Spotify code.
To follow Diamyd Medical’s journey and stay updated on their latest clinical milestones, follow them on LinkedIn here.
Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes. Its lead candidate, retogatein (rhGAD65), is an investigational antigen-specific immunotherapy designed to preserve endogenous insulin production in genetically defined patient populations. The company is advancing retogatein through late-stage clinical development and is establishing in-house biomanufacturing capabilities in Umeå, Sweden.